ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript

Key event: ProQR says it has been exclusively focused since 2022 on developing its Axiomer ADAR-mediated RNA‑editing platform and is building a wholly‑owned pipeline. CFO Dennis Hom emphasized the company’s homegrown IP position and described ProQR as a pioneer in RNA editing, signaling a strategy centered on internal innovation rather than external partnerships.

Analysis

ProQR's reported emphasis on a proprietary RNA-editing platform creates a two-way competitive dynamic: the company can monetize via partnerships/licensing, but real value accrues only if it clears early clinical and manufacturing inflection points. A non-obvious beneficiary of any platform success will be specialty oligonucleotide/CDMO providers — scaling chemically stabilized guide strands and reproducible ADAR recruitment chemistry will force outsized spend with a handful of suppliers, tightening their pricing power and margins.

Primary near-term risks are executional rather than conceptual. The most likely value-killing events are off-target edits or manufacturing delays that push first-in-human or dose-escalation windows beyond 6-12 months; these produce >50% downside in typical platform biotechs because capital markets reprice binary science risk harshly. Conversely, discrete derisking catalysts that could re-rate the equity in 3-12 months are non-dilutive strategic partnerships, a clear regulatory path from a major agency, or early human PD/safety signals that demonstrate controllable on-target editing.

From a positioning standpoint, the market is likely underestimating time-to-revenue and overestimating the moat from early IP breadth — breadth deters some entrants but also invites litigation and cross-licensing, which can delay commercialization. That creates a trade opportunity to capture asymmetric upside from a successful derisking (partnership/positive FIH readout) while limiting downside via hedges tied to clinical timelines and supplier exposure.

Key Decisions for Investors

• Buy PRQR (stock) with protective puts: Establish a tactical long position equal to 0.25–0.5% of NAV, paired with 12-month puts 25–30% OTM to cap downside; time horizon 6–18 months. Risk/reward: if platform shows partnership or positive PD within 6–12 months, aim for 2.5–4x upside; capped loss ~25–30% net of hedge premium if negative readouts or delays occur.
• Options leverage alternative: Buy 9–12 month PRQR calls (ITM or 20–30% OTM depending on cost) sized to 0.15–0.3% of NAV for asymmetric upside into FIH/partnership catalysts; accept 100% option loss as defined downside. Target 3:1 payoff if catalysts succeed within the period.
• Pair trade to isolate platform vs execution: Long PRQR (0.3% NAV) / short a near-term binary CRISPR/RNA-editing small-cap with an imminent readout (size matched for beta) to isolate ProQR’s platform optionality from sector risk; unwind on first positive sector catalyst or at 6 months.
• Supply-chain play: Overweight Thermo Fisher (TMO) or Twist (TWST) by small active weight (0.5–1% NAV) on a 12–24 month horizon to capture increased demand for oligo/CDMO services if RNA editing scales. Risk: broader cyclical softness in biotech funding could compress volumes and delay upside.
• Hard-stop and monitoring: Reduce/close PRQR exposure on any missed IND-enabling milestones or initiation pushed >12 months; set automatic review if stock falls 30–40% or if IP litigation is filed — these are the highest-likelihood drivers of >50% permanent impairment.